The Trump administration’s drug discount website, TrumpRx, currently lists 92 brand-name medications from 15 pharmaceutical companies, according to an analysis of Food and Drug Administration (FDA) data. While the administration has reached agreements with 17 drugmakers to lower costs in exchange for relief from potential tariffs, the current offerings represent approximately 12% of the more than 800 brand-name drugs produced by those participating companies.
The website was launched in February 2026 following a 2025 executive order intended to align U.S. drug prices with those of other wealthy nations. The administration negotiated deals with companies including Pfizer, Eli Lilly, and Johnson & Johnson. Under these agreements, the companies provide direct-to-consumer discounts on select products via the government portal.
According to financial filings and FDA records, several high-revenue medications are excluded from the platform. For example, Pfizer has listed 30 of its 178 brand-name drugs, but the blood thinner Eliquis and the cancer treatment Ibrance are not currently available for discount on the site. Other missing categories include various treatments for HIV and certain inflammatory conditions.
President Trump described the initiative during its launch as a significant milestone in healthcare reform. Health policy researchers, such as Dr. Ben Rome of Brigham and Women's Hospital, noted that participating companies have so far applied the discount model to a limited number of products rather than their full portfolios. The administration previously stated it would use regulatory tools, including tariffs, if companies did not voluntarily lower prices.